Merck Announces FDA Breakthrough Therapy Designation for Inves...
DARMSTADT, Germany, Sept. 11, 2019 /PRNewswire-AsiaNet/ -- - Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan- MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate ...
Authors: LATEST ASIANET NEWS RELEASES